重症患者临终撤除生命支持期间的疼痛管理:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、EMBASE、Cochrane系统评价数据库和Virtual Health Library至2019年3月,纳入13项评估成人ICU临终撤除生命支持期间疼痛管理药物治疗的研究。研究来自美国(38%)、加拿大(31%)和荷兰(31%),11项为单队列研究,12项纽卡斯尔-渥太华量表评分低于7分。最常用阿片类药物为吗啡(使用率60%,95%CI 48-71%),最常用镇静剂为咪达唑仑(使用率28%,95%CI 23-32%)。临终过程中吗啡剂量合并平均增加2.6 mg/h(95%CI 1.2-4)。作者结论认为疼痛控制以阿片类药物联合辅助苯二氮䓬类为主,剂量超过指南推荐,尽管指南一致,但临终关怀实践存在显著异质性。
要点
- 在成人ICU撤除生命支持期间,最常用阿片类药物为吗啡(使用率60%,95%CI 48-71%),最常用镇静剂为咪达唑仑(使用率28%,95%CI 23-32%)。
- 临终过程中吗啡剂量合并平均增加2.6 mg/h(95%CI 1.2-4)。
- 作者结论指出疼痛控制以阿片类药物联合辅助苯二氮䓬类为主,剂量超过指南推荐。
- 尽管指南一致,但临终关怀实践存在显著异质性。
- 纳入研究中11项为单队列研究,12项纽卡斯尔-渥太华量表评分低于7分。
适用人群与场景
- 成人重症患者,在ICU临终时正在接受生命支持限制或撤除。
- 纳入的研究中,患者平均年龄59至71岁,59-100%接受机械通气,47-100%的患者进行了生命支持撤除。
处置流程与药物剂量
- 最常用的阿片类药物为吗啡(使用率60%,95%CI 48-71%),最常用的镇静剂为咪达唑仑(使用率28%,95%CI 23-32%)。
- 临终过程中吗啡剂量合并平均增加2.6 mg/h(95%CI 1.2-4)。
研究设计与关键结果
- 该系统评价与Meta分析共纳入13项研究,研究来自美国(38%)、加拿大(31%)和荷兰(31%)。
- 11项研究为单队列研究,12项研究的纽卡斯尔-渥太华量表评分低于7分。
- 患者平均年龄范围为59至71岁,59-100%接受机械通气,47-100%的患者进行了生命支持撤除。
- 最常用阿片类药物为吗啡,使用率60%(95%CI 48-71%);最常用镇静剂为咪达唑仑,使用率28%(95%CI 23-32%)。
- 临终过程中吗啡剂量合并平均增加2.6 mg/h(95%CI 1.2-4)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析。
- 纳入研究多为单队列研究(11项),且多数研究质量评分较低(12项纽卡斯尔-渥太华量表评分低于7分)。
- 作者结论指出尽管指南一致,但临终关怀实践存在显著异质性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为疼痛控制以阿片类药物联合辅助苯二氮䓬类为主,剂量超过指南推荐。
- 作者指出尽管指南一致,但临终关怀实践存在显著异质性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To review and summarize the most frequent medications and dosages used during withholding and withdrawal of life-prolonging measures in critically ill patients in the intensive care unit.
METHODS: We searched PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and the Virtual Health Library from inception through March 2019. We considered any study evaluating pharmaceutical interventions for pain management during the withholding or withdrawing of life support in adult critically ill patients at the end-of-life. Two independent investigators performed the screening and data extraction. We pooled data on utilization rate of analgesic and sedative drugs and summarized the dosing between the moment prior to withholding or withdrawal of life support and the moment before death.
RESULTS: Thirteen studies met inclusion criteria. Studies were conducted in the United States (38%), Canada (31%), and the Netherlands (31%). Eleven studies were single-cohort and twelve had a Newcastle-Ottawa Scale score of less than 7. The mean age of the patients ranged from 59 to 71 years, 59-100% were mechanically ventilated, and 47-100% of the patients underwent life support withdrawal. The most commonly used opioid and sedative were morphine [utilization rate 60% (95% CI 48-71%)] and midazolam [utilization rate 28% (95% CI 23-32%)], respectively. Doses increased during the end-of-life process (pooled mean increase in the dose of morphine: 2.6 mg/h, 95% CI 1.2-4).
CONCLUSIONS: Pain control is centered on opioids and adjunctive benzodiazepines, with dosages exceeding those recommended by guidelines. Despite consistency among guidelines, there is significant heterogeneity among practices in end-of-life care.
参考来源
- Laserna A, Durán-Crane A, López-Olivo MA, et al. Pain management during the withholding and withdrawal of life support in critically ill patients at the end-of-life: a systematic review and meta-analysis. Intensive Care Med. 2020. PMID: 32833041. doi:10.1007/s00134-020-06139-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。